Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 5

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 5
---
ov

Chief Executive Officer

Miami, Florida

REFERENCES TO ADDITIONAL INFORMATION

This proxy statement incorporates information by reference that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission website, www.sec.gov, or upon your written or oral request by contacting Telomir Pharmaceuticals, Inc., Attention: Investor Relations, 100 SE 2nd St, Suite 2000, #1009, Miami, Florida 33131, by calling (786) 396-6723.

To ensure timely delivery of these documents, any request should be made no later than , 2025 to receive them before the TELO virtual annual meeting.

For additional details about where you can find information about TELO, please see the section titled “ Where You Can Find More Information” beginning on page 77 of this proxy statement.

<div align='center'>ABOUT THIS DOCUMENT</div>

Telomir Pharmaceuticals, Inc., which we refer to herein as the “Company,” “TELO,” “we,” “our,” or “us” (unless otherwise indicated), is providing these proxy materials in connection with the solicitation by our board of directors of proxies to be voted at our Annual Meeting to be held exclusively online via live audio-only webcast on December 30, 2025, at 10:00 A.M. Eastern Time, or at any adjournment or postponement thereof. This proxy statement and the enclosed proxy card will be mailed to each stockholder entitled to notice of, and to vote at, the Annual Meeting of stockholders commencing on or about .

You are cautioned not to rely on any information other than the information contained in or incorporated by reference into this proxy statement. No one has been authorized to provide you with information that is different from that contained in or incorporated by reference into this proxy statement. This proxy statement is dated , 2025. You should not assume that the information contained in this proxy statement is accurate as of any other date, nor should you assume that the information incorporated by reference into this proxy statement is accurate as of any date other than the date of such incorporated document. The mailing of this proxy statement to our stockholders will not create any implication to the contrary.

This proxy statement does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction